Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jeroen van den Brakel"'
Autor:
Ida H. Hiemstra, Kim C.M. Santegoets, Maarten L. Janmaat, Bart E.C.G. De Goeij, Wessel Ten Hagen, Sanne van Dooremalen, Peter Boross, Jeroen van den Brakel, Sieto Bosgra, Grietje Andringa, Berris van Kessel-Welmers, Dennis Verzijl, Richard G. Hibbert, Kristine A. Frerichs, Tuna Mutis, Niels W.C.J. van de Donk, Tahamtan Ahmadi, David Satijn, A. Kate Sasser, Esther C.W. Breij
Publikováno v:
EBioMedicine, Vol 93, Iss , Pp 104663- (2023)
Summary: Background: HexaBody®-CD38 (GEN3014) is a hexamerization-enhanced human IgG1 that binds CD38 with high affinity. The E430G mutation in its Fc domain facilitates the natural process of antibody hexamer formation upon binding to the cell surf
Externí odkaz:
https://doaj.org/article/f33bd39a5fdd41bc885381f56bdbe832
Autor:
Janine Schuurman, Martine E.D. Chamuleau, Paul W. H. I. Parren, Jeroen van den Brakel, Ronald P. Taylor, Marije B. Overdijk, Hilma J. van der Horst, Simone C. Oostindie, Hendrik J. Rademaker, Frank J. Beurskens, Juliette van den Noort, Berris van Kessel, Esther C.W. Breij, Margaret A. Lindorfer, Kristin Strumane, Laurens P. Kil, Tuna Mutis, Edward Van Den Brink
Publikováno v:
Blood Cancer Journal, 10(3). NATURE PUBLISHING GROUP
Oostindie, S C, van der Horst, H J, Kil, L P, Strumane, K, Overdijk, M B, van den Brink, E N, van den Brakel, J H N, Rademaker, H J, van Kessel, B, van den Noort, J, Chamuleau, M E D, Mutis, T, Lindorfer, M A, Taylor, R P, Schuurman, J, Parren, P W H I, Beurskens, F J & Breij, E C W 2020, ' DuoHexaBody-CD37 ®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies ', Blood cancer journal, vol. 10, no. 3, 30 . https://doi.org/10.1038/s41408-020-0292-7
Blood cancer journal, 10(3):30. Nature Publishing Group
Blood Cancer Journal, Vol 10, Iss 3, Pp 1-13 (2020)
Oostindie, S C, van der Horst, H J, Kil, L P, Strumane, K, Overdijk, M B, van den Brink, E N, van den Brakel, J H N, Rademaker, H J, van Kessel, B, van den Noort, J, Chamuleau, M E D, Mutis, T, Lindorfer, M A, Taylor, R P, Schuurman, J, Parren, P W H I, Beurskens, F J & Breij, E C W 2020, ' DuoHexaBody-CD37 ®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies ', Blood cancer journal, vol. 10, no. 3, 30 . https://doi.org/10.1038/s41408-020-0292-7
Blood cancer journal, 10(3):30. Nature Publishing Group
Blood Cancer Journal, Vol 10, Iss 3, Pp 1-13 (2020)
Tetraspanin CD37 has recently received renewed interest as a therapeutic target for B-cell malignancies. Although complement-dependent cytotoxicity (CDC) is a powerful Fc-mediated effector function for killing hematological cancer cells, CD37-specifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b0286279d1b9ed42c80861ce3d6a052
https://www.nature.com/articles/s41408-020-0292-7
https://www.nature.com/articles/s41408-020-0292-7
Autor:
Jeroen van den Brakel, Ida H. Hiemstra, David Satijn, Sanne van Dooremalen, Maarten L. Janmaat, Esther C.W. Breij, Peter Boross, Tahamtan Ahmadi, Bart De Goeij, Laurens P. Kil, Sieto Bosgra, Grietje Andringa, Wessel ten Hagen, A. Kate Sasser
Publikováno v:
Blood. 136:19-20
HexaBody®-CD38 (GEN3014) is a next-generation CD38-specific IgG1 molecule with a hexamerization-enhancing mutation that leads to highly efficient induction of complement-dependent cytotoxicity (CDC) upon binding to CD38 positive tumor cells. HexaBod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a52b2b9f5088c09d60608426f2374f79
https://doi.org/10.1182/blood-2020-140313
https://doi.org/10.1182/blood-2020-140313
Autor:
Tuna Mutis, Paul W. H. I. Parren, Andreas Lingnau, Marije B. Overdijk, Ronald P. Taylor, Martine E.D. Chamuleau, Frank J. Beurskens, Marcel Brandhorst, A. Kate Sasser, Janine Schuurman, Margaret A. Lindorfer, Kristin Strumane, Simone C. Oostindie, Jeroen van den Brakel, Berris van Kessel, Esther C.W. Breij, Hilma J. van der Horst, Laurens P. Kil
Publikováno v:
Cancer Research. 80:4544-4544
CD37 is a tetraspanin expressed on mature B cells where it orchestrates plasma membrane organization, receptor signaling, cell migration and adhesion. As CD37 is abundantly expressed on many mature B cell-derived malignancies, it represents an attrac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e15344396187f92390a98999dcba731c
https://doi.org/10.1158/1538-7445.am2020-4544
https://doi.org/10.1158/1538-7445.am2020-4544
Autor:
Jeroen van den Brakel, Paul W. H. I. Parren, Jessica L. Teeling, Jan G.J. van den Winkel, Luus Wiegman, Ruth R. French, Tom Vink, Tom van Meerten, Wendy J.M. Mackus, Jerry W. Slootstra, Stephen A. Beers, Saskia B. Ebeling, Martin J. Glennie
Publikováno v:
The Journal of Immunology. 177:362-371
We have previously defined a panel of fully human CD20 mAb. Most of these were unexpectedly efficient in their ability to recruit C1q to the surface of CD20-positive cells and mediate tumor lysis via activation of the classical pathway of complement.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6621dbae7fbbd44ef3b7a90c367506bf
https://doi.org/10.4049/jimmunol.177.1.362
https://doi.org/10.4049/jimmunol.177.1.362
Autor:
Jan G. J. van de Winkel, Ruth R. French, Jessica L. Teeling, Martin J. Glennie, Paul W. H. I. Parren, Thomas Valerius, Haichun Huang, Claude H.T. Chan, Mark S. Cragg, Jeroen van den Brakel, C. Erik Hack, Marielle Pluyter, Michael Dechant
Publikováno v:
Blood. 104:1793-1800
Despite the rapid and widespread integration of chimeric CD20 monoclonal antibody (mAb), rituximab, into the management of non-Hodgkin lymphoma, its efficacy remains variable and often modest when used as a single agent. To develop more potent reagen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7e9b3eb7bd52cd5414e1a2dbdefbd3a
https://doi.org/10.1182/blood-2004-01-0039
https://doi.org/10.1182/blood-2004-01-0039
Autor:
Wim K. Bleeker, Chao Wu, Guus A.M.S. van Dongen, Jeroen van den Brakel, Henry Witteveen, Hugo A. Gratama van Andel, Brendan Vastenhouw, Erwin L. A. Blezer, Max A. Viergever, Freek J. Beekman, Mischa Houtkamp, Marijke Stigter-van Walsum, Ruud M. Ramakers, Woutjan Branderhorst, Frans van der Have
Publikováno v:
Journal of Nuclear Medicine, 55(5), 830-837. Society of Nuclear Medicine Inc.
Journal of nuclear medicine, 55(5), 830-837. Society of Nuclear Medicine Inc.
Branderhorst, W, Blezer, E L A, Houtkamp, M, Ramakers, R M, van den Brakel, J H, Witteveen, H, van der Have, F, van Andel, H A G, Vastenhouw, B, Wu, C, Stigter-van Walsum, M, van Dongen, G A M S, Viergever, M A, Bleeker, W K & Beekman, F J 2014, ' Three-Dimensional Histologic Validation of High-Resolution SPECT of Antibody Distributions Within Xenografts ', Journal of Nuclear Medicine, vol. 55, no. 5, pp. 830-837 . https://doi.org/10.2967/jnumed.113.125401
Journal of nuclear medicine, 55(5), 830-837. Society of Nuclear Medicine Inc.
Branderhorst, W, Blezer, E L A, Houtkamp, M, Ramakers, R M, van den Brakel, J H, Witteveen, H, van der Have, F, van Andel, H A G, Vastenhouw, B, Wu, C, Stigter-van Walsum, M, van Dongen, G A M S, Viergever, M A, Bleeker, W K & Beekman, F J 2014, ' Three-Dimensional Histologic Validation of High-Resolution SPECT of Antibody Distributions Within Xenografts ', Journal of Nuclear Medicine, vol. 55, no. 5, pp. 830-837 . https://doi.org/10.2967/jnumed.113.125401
Longitudinal imaging of intratumoral distributions of antibodies in vivo in mouse cancer models is of great importance for developing cancer therapies. In this study, multipinhole SPECT with sub-half-millimeter resolution was tested for exploring int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77239724bb08ede1ee8cfd67a0a2813a
https://pubmed.ncbi.nlm.nih.gov/24686779
https://pubmed.ncbi.nlm.nih.gov/24686779
Autor:
Jeroen van den Brakel, Jan G. J. van de Winkel, Jeroen J. Lammerts van Bueren, Wim K. Bleeker, Marije B. Overdijk, Sandra Verploegen, Paul W. H. I. Parren, Tom Vink
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 187(6)
Ab-dependent cellular cytotoxicity (ADCC) is recognized as a prominent cytotoxic mechanism for therapeutic mAbs in vitro. However, the contribution of ADCC to in vivo efficacy, particularly for treatment of solid tumors, is still poorly understood. F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4d2f5a2d999b6ce15bdb32c677e4a6f
https://pubmed.ncbi.nlm.nih.gov/21832160
https://pubmed.ncbi.nlm.nih.gov/21832160
Autor:
Evert de Vries, Ada M. Kruisbeek, Jeroen van den Brakel, Mariëlle C. Haks, Jannie Borst, Tanina A. Cordaro, John B. A. G. Haanen, Paul Krimpenfort
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 166(4)
At least four different CD3 polypeptide chains are contained within the mature TCR complex, each encompassing one (CD3gamma, CD3delta, and CD3epsilon) or three (CD3zeta) immunoreceptor tyrosine-based activation motifs (ITAMs) within their cytoplasmic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40934a7c9dc8a6e309cbd98b83b352e7
https://pubmed.ncbi.nlm.nih.gov/11160319
https://pubmed.ncbi.nlm.nih.gov/11160319